|
Categories |
|
Immune Disorders and Inflammation |
|
|
Biotechnology
Cancer
Consumer
Customer
Relationship Management
Drug
Delivery
eHealthcare
Pharma
eHealthcare
Physician
Generics
Healthcare
Medical
Devices
OTC
Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic
Areas:
- Cardiovascular
- Central
Nervous System
- Immune
Disorders and Inflammation
- Infectious
Diseases
- Oncology
-
Women'sHealth
|
|
|
1- Pipeline Insight: Disease Modification In Rheumatoid Arthritis - Uptake Inhibited By Anti-TNFs 05-Oct-2005
Detailed analysis of Disease Modifying Anti-Rheumatic Drugs (DMARDs) in the pipeline, including an assessment of the latest trial data and clinical strategies. Includes an indication specific ten-year forecast for future key products.
------------------------------------------------------------------------------------------------------------------------- |
2- Commercial and Pipeline Perspectives: Lower GI
Disorders - Remicade Leads Growth as Novel Biologics Compete for
Market Share in Inflammatory Bowel Disease 29-July-2004
Detailed analysis of R&D
products for the treatment of IBD in seven major
markets.
------------------------------------------------------------------------------------------------------------------------- |
3- Commercial and Pipeline Perspectives: Rheumatoid
Arthritis - Novel Biologics Drive
Innovation 23-June-2004
A detailed analysis and ten year
forecast to ATC4 level by class, molecule & brand of currently
marketed and pipeline RA drugs in the seven major markets. The
analysis is delivered as a word report, PowerPoint presentation and
excel forecasts.
------------------------------------------------------------------------------------------------------------------------- |
4- Stakeholder Insight: Rheumatoid Arthritis - DMARDs
Gain Ground as Biologics Competition
Intensifies 7-Jan-2004
Detailed investigation of prescribing patterns and
reasons underlying physician choice, based on Stakeholder Insight
survey of 180 treating physicians.
-------------------------------------------------------------------------------------------------------------------------
|
5- Disease Modifying Osteoarthritis Drugs - The Search
for the ‘Holy Grail’ Continues 25-Dec-2003
Pipeline drugs, and possible methods of action for
future therapeutics, and a comparative analysis of the most
promising therapies.
-------------------------------------------------------------------------------------------------------------------------
|
6- Stakeholder Perspectives: Asthma - Improvements to
Combination Inhalers Will Satisfy a Growing Patient Base
19-Dec-2003
Using the findings of a comprehensive physician survey
and in-depth interviews with key respiratory opinion leaders, this
report investigates current and future prescribing trends and
driving factors in the asthma in the seven major markets.
-------------------------------------------------------------------------------------------------------------------------
|
7- Stakeholder Insight: Osteoarthritis - COX-2s wear down
traditional NSAID use 16-Dec-2003
Insight
into trends in current prescribing practices, based on interviews
with prescribing physicians in the 7 major
markets.
-------------------------------------------------------------------------------------------------------------------------
|
8- Neuropathic Pain Insight - Life Beyond Gabapentin
25-Feb-2004
The current neuropathic pain market suffers from lack
of public awareness, poor physician education (often leading to
misdiagnosis), under-utilization of effective drugs, inappropriate
use of medications, and regional variations in drug
availability.
-------------------------------------------------------------------------------------------------------------------------
|
9- Epidemiology: Osteo & Rheumatoid Arthritis -
Defining the patient populations 15-Oct-2003
This Brief examines a variety of
epidemiological studies and other sources to provide insight into
the size and demographics of the osteoarthritis (OA) and rheumatoid
arthritis (RA) populations in the seven major markets.
-------------------------------------------------------------------------------------------------------------------------
|
10- Commercial Insight: Asthma and COPD - Combinations
breathe life into the asthma and COPD markets 14-Oct-2003
Using IMS
and company published data, as well as assessment of pipeline
therapies and opinion leader insight, this report investigates the
future direction and value of the global asthma and COPD
market..
-------------------------------------------------------------------------------------------------------------------------
|
11- Cystic Fibrosis - Countdown to a Cure?
6-Oct-2003
An overview of Cystic Fibrosis symptoms and their
cause. Includes disease epidemiology, overview of current marketed
therapies and an in-depth analysis of pipeline products from
preclinical to phase
III.
-------------------------------------------------------------------------------------------------------------------------
|
12- Pipeline and Commercial Perspectives: Psoriasis and
Atopic Dermatitis - Reimbursement the key as biologics and TIMs
transform disease markets
22-Sep-2003
Analysis
of pipeline issues concerning drugs in clinical trials in the
Psoriasis market and commercial issues concerning currently marketed
drugs in the Atopic Dermatitis
market.
-------------------------------------------------------------------------------------------------------------------------
|
13- Food Allergies: New Treatments Are Nothing To Sneeze
At 18-Aug-2003
Analyzes current treatment practices, diagnostics and
unmet needs in food allergies, and provides a look ahead at some
promising strategies to meet these needs.
-------------------------------------------------------------------------------------------------------------------------
|
14- Commercial Insight: Osteoarthritis & Rheumatoid
Arthritis - New Growth In A Mature Market 29-Jul- 2003
Analysis
of the current dynamics of the arthritis market, and the factors
that will affect the leading drugs and major players in the future.
-------------------------------------------------------------------------------------------------------------------------
|
15- Gastrointestinal Disease Update: Digestive Disease
Week 2003 3-Jul-2003
A review of
findings from Digestive Disease Week, May 17-22 2003, held in
Orlando,
Florida.
-------------------------------------------------------------------------------------------------------------------------
|
16- Key Trends in the Asthma and COPD Market - Uncertain
times for novel inhalation devices 27-Jun-2003
Factors
driving change in the asthma/COPD market, and the most promising new
therapies and drug delivery
technologies.
-------------------------------------------------------------------------------------------------------------------------
|
17- Systemic Lupus Erythematosus: The Wait For
Lupus-Specific Treatments 30-May-2003
Evaluates
the current and future SLE market by examining epidemiology, current
treatment practices and pipeline drugs designed to treat
lupus.
-------------------------------------------------------------------------------------------------------------------------
|
18- Pipeline
Insight: Rheumatoid Arthritis and Osteoarthritis - Striving for
innovation among me-toos 2-Apr-2003
Early-stage products with novel mechanisms of action
hold out promise.
-------------------------------------------------------------------------------------------------------------------------
|
19- Stakeholder Perspectives: Gastrointestinal Disorders -
PPIs for GERD and PUD: Never Had It So Good, or As Good As It
Gets? 6-Mar-2003
Analysis of Gastroesophageal
Reflux Disease (GERD) & Peptic Ulcer Disease (PUD) in the seven
major markets from the perspective of marketed & pipeline drugs,
epidemiology & treatment practices. It includes transcripted
interviews with opinion
leaders.
-------------------------------------------------------------------------------------------------------------------------
|
20- Current and Future Diabetes Blockbusters: Non-injected
Insulins- Hype, Hope or Reality? 13-Jan-2003
Achieving blockbuster status - the keys to
success.
-------------------------------------------------------------------------------------------------------------------------
|
21- Treatment Algorithms: Chronic Obstructive Pulmonary
Disease - Spiriva Set to Revolutionize Clinical
Practice
13-Jan-2003
Current
treatment regimens and future trends for an under-diagnosed
indication.
-------------------------------------------------------------------------------------------------------------------------
|
22- Claritin: Easing the Pain of Blockbuster Patent
Expiry 6-Jan-2003
-------------------------------------------------------------------------------------------------------------------------
|
| |
